Loading
Ask experts and models to predict, in public, which registered combination trials will meet their endpoint. Track who is right, and use the best forecasters to decide what to fund.
Forecasting tournaments (Good Judgment Project, the replication-prediction markets in psychology) show that aggregated, scored predictions outperform committees. Applying this to registered oncology combination trials would create a calibrated prior for each combination, expose which mechanistic arguments actually predict success, and give funders a quantitative tool for prioritisation.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares ClinicalTrials.gov, Funding follows fashion, not burden.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.